Why the study?
Pathological ADAM17 activation may promote inflammation and diminish ACE2 tissue protection through proteolytic shedding, prompting examination of plasma soluble ACE2 and angiotensin profiles in relation to COVID-19 outcomes.
Is an upward trajectory of soluble ACE2 associated with increased 90-day mortality and end-organ injury in patients admitted for COVID-19?
Population
242 consecutive patients admitted for COVID-19
Comparison
Baseline vs repeated plasma soluble ACE2 and angiotensin profiles at 7 days
Design
Prospective cohort study
Follow-up
90 days
Loading...
Rising soluble ACE2 trajectories flag higher COVID-19 mortality risk; leaves open whether ADAM17-targeted interventions warrant trials.
Is an upward trajectory of soluble ACE2 associated with increased 90-day mortality and end-organ injury in patients admitted for COVID-19?
An upward trajectory of soluble ACE2 and dysregulation of angiotensin peptides are associated with increased mortality and end-organ injury in COVID-19 patients.
A 2021 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: